The REDEFINE trials
Cagrilintide's evidence base is genuinely strong for an unapproved drug: a clean monotherapy dose-finding trial, a phas…
From a dose-finding trial to phase 3
Cagrilintide's evidence base is genuinely strong for an unapproved drug: a clean monotherapy dose-finding trial, a phase 1b combination study, a phase 2 in diabetes, and two large phase 3 REDEFINE trials in NEJM. This unit walks that ladder and the honest debate over how impressive the phase 3 result really was.
It also teaches a durable skill: why you must cite the peer-reviewed paper, not the press-release topline, when a drug's headline number becomes a market event.
Key terms
The evidence ladder
Cagrilintide climbed a clean development ladder, each rung answering a specific question. This orderly progression, from dose-finding to combination safety to phase 3, is part of why the program is taken seriously despite being a single manufacturer's effort.
Notice how each rung sets up the next: monotherapy dose-finding chose 2.4 mg, the phase 1b proved the combination was safe, the phase 2 confirmed it worked in diabetes, and only then did the large phase 3 trials run. This is textbook drug development, and it is why the REDEFINE results arrived on a solid mechanistic and dose foundation rather than as an isolated result.
AdvancedWhy the phase 1b interaction study mattered
Before a combination can be tested for efficacy, you must prove the two drugs are safe together and do not interfere. The Enebo 2021 phase 1b did exactly that, showing cagrilintide and semaglutide could be co-administered without a meaningful pharmacokinetic interaction. Without that unglamorous safety rung, the co-formulated single-pen phase 3 program could not have been designed.